| Issuer | % of Class | Filed | |||
|---|---|---|---|---|---|
|
ImmunityBio, Inc.
13D/A
Amendment 13
IBRX · 45256X103
|
64.8% |
8/6/2026
Event 7/31/2026
|
|||
| Cambridge Equities, LP | 24.7% | ||||
| MP 13 Ventures, LLC | 24.7% | ||||
| NantWorks, LLC | 9.3% | ||||
| Nant Capital, LLC | 29.6% | ||||
| California Capital Equity, LLC | 10.0% | ||||
| Patrick Soon-Shiong | 64.8% | ||||
|
ImmunityBio, Inc.
13D/A
Amendment 12
IBRX · 45256X103
|
66.3% |
2/25/2026
Event 2/23/2026
|
|||
| Cambridge Equities, LP | 25.5% | ||||
| MP 13 Ventures, LLC | 25.5% | ||||
| NantWorks, LLC | 9.6% | ||||
| Nant Capital, LLC | 30.3% | ||||
| California Capital Equity, LLC | 10.4% | ||||
| Patrick Soon-Shiong | 66.3% | ||||
|
ImmunityBio, Inc.
13D/A
Amendment 11
IBRX · 45256X103
|
68.9% |
11/10/2025
Event 11/10/2025
|
|||
| Cambridge Equities, LP | 26.6% | ||||
| MP 13 Ventures, LLC | 26.6% | ||||
| NantWorks, LLC | 10.0% | ||||
| NantMobile, LLC | 4.8% | ||||
| Nant Capital, LLC | 31.5% | ||||
| California Capital Equity, LLC | 10.8% | ||||
| Patrick Soon-Shiong | 68.9% | ||||
Includes filings since 12/18/2024, when the SEC began requiring structured 13D and 13G data.